2.

广泛期小细胞肺癌二线化疗总生存期的单因素分析

Univariate analysis of overall survival (OS) in extensive-stage SCLC patients who received second-line chemotherapy

Factors		OS (month)	95%CI (month)	χ2	P
Group A：CE/EP regimens; Group B: regimens containing TPT; Group C: regimens containing CCPT-11; Group D: regimens containing TAX/DXL; Group E: regimens containing IFO; Group F: other regimens. PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response.
Sex				4.059	0.044
	Male	6.2	4.35-8.05
	Female	10.7	7.84-13.56
Age (yrs)				1.040	0.308
	≥60	7.2	4.81-9.65
	＜60	6.9	5.09-8.71
Smoking history				6.252	0.012
	Yes	5.9	4.41-7.45
	No	9.4	4.46-14.41
ECOG PS				23.233	＜0.001
	0-1	8.2	6.21-10.25
	2-4	2.7	1.43-4.03
Brain metastasis				1.772	0.183
	Yes	6.8	5.24-8.42
	No	7.7	5.89-9.57
Liver metastasis				6.284	0.012
	Yes	5.7	3.60-7.86
	No	7.7	5.08-10.38
Bone metastasis				10.263	0.001
	Yes	4.7	3.89-5.45
	No	9.1	6.90-11.24
Adrenal metastasis				0.589	0.443
	Yes	5.9	0.00-12.16
	No	7.2	5.55-8.85
Malignant pleural fluid				0.494	0.482
	Yes	9.3	6.23-12.43
	No	6.8	5.18-8.48
Second-line chemotherapy regimen				1.491	0.914
	Group A	11.0	0.00-31.43
	Group B	7.9	6.53-9.33
	Group C	6.8	5.25-8.41
	Group D	4.7	4.11-5.23
	Group E	6.2	0.00-14.53
	Group F	7.2	5.40-9.75
Curative effect of first-line chemotherapy				6.342	0.096
	PD	5.9	0.00-11.95
	SD	6.8	4.96-8.70
	PR+CR	7.7	5.24-10.22
	Unknown	1.3	0.00-3.41
Recurrence status				6.769	0.034
	Resistant	6.8	5.38-8.28
	Sensitive	7.0	4.06-10.00
	≥6 months	14.1	5.54-22.66